Search research articles
Contact Us
Filters
Showing results (21-30 of 72) with videos related to
Page
of 8
Sort By:
American Journal of Hematology
|
April 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference
Ajai Chari, Caitlin Costello, Amrita Krishnan, et al.
Blood Advances
|
July 23, 2024
Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience
Nilesh M Kalariya, Michelle A T Hildebrandt, Doris K Hansen, et al.
Frontiers in Oncology
|
November 12, 2025
Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease
Ziad Abuhelwa, Fnu Amisha, Wenyi Fan, et al.
Cancers
|
June 10, 2022
Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization
Laura B Oswald, Xiaoyin Li, Rodrigo Carvajal, et al.
Blood Advances
|
January 5, 2024
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality
Kai Rejeski, Yucai Wang, Doris K Hansen, et al.
Transplantation and Cellular Therapy
|
October 20, 2025
Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia
Eric Gaskill, Omar Albanyan, Syeda Mahrukh Hussnain Naqvi, et al.
Clinical Epidemiology
|
June 2, 2026
Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple Myeloma
Doris K Hansen, Omar Alexis Castaneda Puglianini, Ariel Grajales-Cruz, et al.
Frontiers in Immunology
|
June 25, 2024
Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma
Doris K Hansen, Binod Dhakal, Mehdi Hamadani, et al.
Current Medical Research and Opinion
|
April 30, 2026
Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms
Doris K Hansen, Omar Alexis Castaneda Puglianini, Ariel Grajales-Cruz, et al.
Advances in Therapy
|
March 24, 2026
FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA
Sikander Ailawadhi, Doris K Hansen, Binod Dhakal, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 72) with videos related to
Sort By:
Page
of 8
American Journal of Hematology
|
April 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference
Ajai Chari, Caitlin Costello, Amrita Krishnan, et al.
Blood Advances
|
July 23, 2024
Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience
Nilesh M Kalariya, Michelle A T Hildebrandt, Doris K Hansen, et al.
Frontiers in Oncology
|
November 12, 2025
Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease
Ziad Abuhelwa, Fnu Amisha, Wenyi Fan, et al.
Cancers
|
June 10, 2022
Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization
Laura B Oswald, Xiaoyin Li, Rodrigo Carvajal, et al.
Blood Advances
|
January 5, 2024
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality
Kai Rejeski, Yucai Wang, Doris K Hansen, et al.
Transplantation and Cellular Therapy
|
October 20, 2025
Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia
Eric Gaskill, Omar Albanyan, Syeda Mahrukh Hussnain Naqvi, et al.
Clinical Epidemiology
|
June 2, 2026
Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple Myeloma
Doris K Hansen, Omar Alexis Castaneda Puglianini, Ariel Grajales-Cruz, et al.
Frontiers in Immunology
|
June 25, 2024
Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma
Doris K Hansen, Binod Dhakal, Mehdi Hamadani, et al.
Current Medical Research and Opinion
|
April 30, 2026
Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms
Doris K Hansen, Omar Alexis Castaneda Puglianini, Ariel Grajales-Cruz, et al.
Advances in Therapy
|
March 24, 2026
FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA
Sikander Ailawadhi, Doris K Hansen, Binod Dhakal, et al.
Page
of 8